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Identification of selective tubulin inhibitors as potential
anti-trypanosomal agents
Rati Lama , Ranjodh Sandhu , Bo Zhong , Bibo Li , Bin Su
Human African trypanosomiasis, also known as sleeping sick
ness, is a vector borne parasitic disease and also a serious health
threat to a large number of people living in sub Saharan Africa
where health systems are least effective, or even non existent.1–3
Trypanosoma brucei gambiense (T. b. gambiense) and Trypanosoma
brucei rhodesiense (T. b. rhodesiense) are the etiological parasites
of sleeping sickness in humans. In West and Central Africa, T. b.
gambiense is the major parasite to cause the disease, while in
sub Saharan Africa, T. b. rhodesiense predominates. These subspe
cies of trypanosome are responsible for the West and East African
forms of the disease, respectively.2 The main difference between
the two infections is the rate of progression from the blood/lym
phatic stage to the cerebral stage. T. b. gambiense infection is
chronic because it takes months for the disease to progress. By con
trast, the infection of T. b. rhodesiense is more acute, and could
reach the cerebral stage in one to three weeks. For, T. b. gambiense,
humans are the main hosts. However, wild and domestic animals,
especially cattle, are the major reservoirs for T. b. rhodesiense.1 A
third closely related subspecies, Trypanosoma brucei brucei (T. b.
brucei), is less infectious to humans, but is responsible for many
cases of nagana in cattle. It significantly limits the agricultural
development in Africa.4,5 As T. b. brucei shares many features with
T. b. gambiense and T. b. rhodesiense (such as antigenic variation), it
is often used as a model for human infections in laboratory and
animal studies.
The current chemotherapy of the human trypanosomiasis relies
on only five drugs including Suramin, Pentamidine, Melarsoprol,
Eflornithine and Nifurtimox Eflornithine combination.6 The main
drawbacks of these drugs are: (1) high toxicity to the hosts, which
is mainly due to their poor selectivity to the parasite cells than the
mammalian cells; (2) these agents have to be administered via
intramuscular or intravenous injections; (3) they have very narrow
anti trypanosomiasis spectrum; and (4) treatment using these
drugs needs the high cost of hospitalization. Overall, these drugs
are not successful in the treatment of the disease, and there is a
general lack of effective, inexpensive chemotherapeutic agents
for the treatment of human African trypanosomiasis. Clearly, im
proved chemotherapeutics with better selectivity to the trypano
somes are needed to effectively battle this disease.5,7,8
Tubulin containing structures are important for many impor
tant cellular functions, including chromosome segregation during
cell division, intracellular transport, development and mainte
nance of cell shape, cell motility, and distribution of molecules
on cell membranes.9 Tubulin is a very attractive target in anti
cancer drug discovery field, and several successful tubulin binders
are the first line chemotherapeutic agents in clinic.10 Tubulin also
plays an essential role during trypanosome cell division. The fast
population doubling rate of trypanosomes makes them highly
dependent on tubulin polymerization/depolymerization.11 More
importantly, tubulin is very critical for the trypanosome locomo
tion, which is an essential function for trypanosomes to survive.
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The T. brucei cell body is roughly cylindrical in shape with tapered
anterior and posterior ends. A single flagellum emerges from the
basal body near the posterior end of the cell. Within the flagellum
is a canonical ‘9+2’ microtubule axoneme that drives flagellar
movement.12 Tubulin inhibitors not only block the T. brucei cell
division but will also affect the locomotion function of flagellum
and lead to cell death.13 The flagellar pocket is known to be an
important structure in the uptake and internalization of molecules
for trypanosomes.14 Such uptake could enhance the binding of the
tubulin inhibitors to intracellular tubulin, particularly in the fla
gella pocket. Therefore, tubulin inhibitors could be effective agents
to suppress flagellar locomotion function.13 These factors indicate
that there are potential advantages of tubulin inhibitors for the
treatment of trypanosomiasis. In addition, identification of binding
pockets uniquely located on T. brucei tubulin would allow develop
ment of selective tubulin inhibitors, which could dramatically re
duce the toxic effects of the anti parasite drugs to the host cells.
Tubulin is a highly conserved protein. Examination of tubulin
sequences from mammalian cells and yeast cells reveals 70 90%
identity. However, differences in susceptibility to antimitotic
agents are known to exist between tubulins from different organ
isms, suggesting that differences of tubulin structures exist among
different species.15 For example, the antifungal compound methyl
N (benzimidazol 2 yl) carbamate shows high selectivity to yeast
tubulin. It has been reported that the compound is at least 300 fold
more potent as an inhibitor of yeast tubulin than that of bovine
brain tubulin.16 In addition, oxfendazole and thiabendazole com
pounds are also more effective to inhibit nematode tubulin poly
merization than mammalian tubulin.17 The results from these
investigations reveal that there are differences in tubulin drug sus
ceptibility for different organisms. Based on the differences of
tubulin in T. brucei and mammalian cells, it is highly expected that
selective tubulin inhibitors could be developed. Some microtubule
disrupting herbicides such as phosphoric thioamide herbicide
amiprophos methyl (APM) and dinitroaniline herbicides exhibit
activity against protozoan parasites by aiming tubulin as the
molecule target.15,17–20 Research has been done to optimize these
compounds to generate more potent and selective tubulin inhibi
tors for T. brucei.15 Werbovetz’s group successfully developed sev
eral drug candidates showing promising in vitro anti parasite
activity and selectivity. However, these compounds did not show
good in vivo potency due to the poor stability.21 However, these
investigations demonstrated the feasibility to generate selective
tubulin inhibitors as anti trypanosomal agents.
To search for selective tubulin inhibitors as better therapeutic
agents to treat sleeping sickness, we firstly examined the inhibitory
activity of several tubulin inhibitors that are current clinical drugs
or in clinical trials for cancer treatment10,22 on T. brucei (T. b. brucei
was used as the representative strain) with 3 (4,5 dimethylthiazol
2 yl) 5 (3 carboxymethoxyphenyl) 2 (4 sulfophenyl) 2H tetrazo
lium (MTS) assay,23 then onmammalian cell growth (SKBR 3 breast
cancer cell line as amodel) withMTT assay.24 Among the few tested
drugs, paclitaxel showed very similar activity on both T. brucei and
SKBR 3 breast cancer cells (Table 1), suggesting that tubulin
binding domain of paclitaxel is very similar in the two organisms.
However, vinblastine and the colchicine domain binders including
colchicine, indibulin,25 nocodazole and ABT75122 exhibited strong
inhibition to mammalian cells but very weak inhibitory effect on
T. brucei growth, which is consistent to other studies focusing on
tubulin inhibitors with T. brucei.26,27 These results suggest that sig
nificant differences exist in the colchicine binding domain between
mammalian and T. brucei tubulins.
Due to the very different biological activities of the well defined
tubulin inhibitors on mammalian and T. brucei cells, we compared
the tubulin amino acid sequence of the two organisms (Table 2).
Bovine tubulin was listed as a representative of mammalian tubu
lin. T. brucei tubulin showed an 85% identity to bovine a tubulin
and 86% identity to bovine b tubulin when analyzed with SWISS
MODEL repository.28,29 It is hard to estimate whether the binding
sites of tubulin inhibitors are very different between mammalian
and T. brucei cells just based on the protein sequence comparison.
However, the difference of certain key amino acids of tubulin is
very likely to affect the tubulin inhibitor’s binding affinity. It has
been reported that Leucine 316 of b Tubulin (Table 2, L316 is
marked in blue) is critical for colchicine activity against bovine
tubulin polymerization.30–32 In T. brucei b tubulin, residue 316 is
changed to Valine, which is expected to greatly decrease the col
chicine binding and presumably explains the weak inhibitory
activity of colchicine on the growth of T. brucei cells (Table 1).
To further illustrate the difference of the colchicine binding do
main of bovine and T. brucei tubulin, a predicated structure of T.
brucei tubulin was generated based on the crystal structure of bo
vine tubulin (PDB1SA0)30 using SWISS MODEL Repository program
(Fig. 1).28,29 The model shows great similarity between T. brucei and
bovine tubulin, since the protein sequence identity is 85%. How
ever, the colchicine binding domain shows clear difference be
tween the two types of tubulins. Several b sheets of the bovine
and the T. brucei tubulin (Fig. 1B, circled area) in the colchicine
binding domain do not overlap well. These b sheets form the bind
ing pocket for colchicine, and are critical for ligand binding. Other
colchicine domain binder including nocodazole, indibulin, and
ABT751 also rely on these b sheets to bind to tubulin.30,33 The dif
ference between the effects of these well defined tubulin inhibi
tors on T. brucei and mammalian cells (Table 1) is also consistent
with the predicated structure difference between the two tubulin
homologous. This significant docking site difference provides a
good foundation for the development of selective colchicine
domain binders for the treatment of sleeping sickness.
We previously developed a class of sulfonamide tubulin inhibi
tors (Table 3) as anti cancer agents.24,34 These inhibitors were
identified to be colchicine domain binders and some of them
exhibited very potent cell cycle arrest and apoptosis inducing
activity in mammalian cells.24 Due to the structural diversity of
their benzamide moiety, we hypothesized that some of the analogs
might selectively inhibit T. brucei growth, since mammalian and T.
brucei tubulin exhibit differences on colchicine binding domain,
particularly at the benzamide moiety binding pocket (Figs. 1 and
2). More specifically, the benzamide moiety of the tubulin inhibi
tors interacts with the b sheets of the colchicine binding domain
as indicated with blue arrows in Figure 2.34 The differences of these
b sheets in T. brucei and mammalian cells will form different bind
ing pockets, and highly likely cause different interactions with dif
ferent benzamide moieties, which will lead to selectivity.
The compounds were tested with T. brucei cell growth assay,
and the IC50s are listed in Table 3. The activities against SKBR 3
breast cancer cells from previous studies24 are listed in the table
for comparison. Several compounds, including 3, 17, 26, 38, and
43, exhibited very specific inhibitory effect on T. brucei growth,
with selectivity index (IC50 inhibiting human cancer cell growth/
IC50 inhibiting T. brucei growth) being five or more. Particularly,
Table 1
Well-defined tubulin inhibitors exhibited growth inhibition to mammalian and T.
brucei cells
Entry IC50 against SKBR-3 breast cancer
cell growth (lM)
IC50 against T. brucei
growth (lM)
Paclitaxel 0.0019 ± 0.0009 0.0046 ± 0.0018
Indibulin 0.033 ± 0.012 114.1 ± 45.5
ABT751 0.74 ± 0.20 82.1 ± 37.0
Colchicine 0.0064 ± 0.0023 14.0 ± 7.2
Vinblastine 0.00091 ± 0.00031 0.41 ± 0.21
Nocodazole 0.084 ± 0.022 44.2 ± 23.5
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four replicates. Cells were grown in RPMI1640 medium in 96-well flat-
bottomed plates for 24 h, and were exposed to various concentrations of test
compounds dissolved in DMSO (final concentration60.1%) in medium for 48 h.
Controls received DMSO vehicle at a concentration equal to that in drug-
treated cells. The medium was removed, replaced by 200 lL of 0.5 mg/ml of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide in fresh
media, and cells were incubated in the CO2 incubator at 37 C for 2 h.
Supernatants were removed from the wells, and the reduced 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide dye was
solubilized in 200 lL /well DMSO. Absorbance at 570 nm was determined on
a SpectraMax Plus384 spectrophotometer (molecular devices).
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